Outset Medical (OM) Investor presentation summary

Market opportunity and industry context

• Addresses a $2.5B acute/post-acute care market and an $8.9B home dialysis market, with over 1,000 care sites and more than 1 million treatments annually.

• Dialysis is a $71B sector in the U.S., with $55B paid by Medicare and 90 million annual treatments.

• Inpatient dialysis is unreimbursed, causing hospitals to lose $5,000–$25,000 per stay for renal failure with dialysis.

• Outsourcing dialysis has led to longer hospital stays, higher costs, and increased risks, including a 5.1-day longer average length of stay and up to $8,500 average loss per inpatient stay.

Product innovation and differentiation

• Tablo is a first-of-its-kind, single-device technology for dialysis, designed to reduce cost and complexity from bedside to ICU.

• Offers a comprehensive enterprise solution with EMR interoperability, data analytics, fleet management, and advanced service/support tools.

• Enables hospitals to bring dialysis in-house, resulting in up to 36% reduction in ICU length of stay, 75% reduction in CLABSI, and 52% cost reduction per treatment hour.

• Over 10,000 nurses and 1,000 physicians trained, with more than 3 million cumulative treatments delivered.

Home dialysis market and adoption

• Home dialysis market is underpenetrated due to reimbursement misalignment, low awareness, and cumbersome technology.

• Tablo addresses these barriers with simplified training (less than 25 hours per patient) and no dialysate prep time, compared to historical devices requiring 100 hours of training and 16–24 hours of prep per week.